Evidence map›Paper›PMID 35624703›Full record

ReviewAntioxidants (Basel, Switzerland)2022

Hepatic Encephalopathy and Melatonin.

Archana Arjunan, Dhiraj Kumar Sah, Young Do Jung, Juhyun Song

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Serum melatonin predicts hepatic encephalopathy in patients with liver cirrhosis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Archana ArjunanDepartment of Anatomy, Chonnam National University Medical School, Hwasun 58128, Korea.ORCID 0000-0001-7947-2614
Dhiraj Kumar SahDepartment of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Korea.ORCID 0000-0003-1857-6887
Young Do JungDepartment of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Korea.ORCID 0000-0003-1209-6786
Juhyun SongDepartment of Anatomy, Chonnam National University Medical School, Hwasun 58128, Korea.ORCID 0000-0002-9165-8507
Chonnam National University Hwasun Hospital · KRChonnam National University · KR

Funding

National Research Foundation of Korea 2019R1F1A1054111National Research Foundation of Korea funded by the Ministry of Education, Science, and Tech-nology 2018R1D1A1B07049918
6 · The paper itself

Abstract

Hepatic encephalopathy (HE) is a severe metabolic syndrome linked with acute/chronic hepatic disorders. HE is also a pernicious neuropsychiatric complication associated with cognitive decline, coma, and death. Limited therapies are available to treat HE, which is formidable to oversee in the clinic. Thus, determining a novel therapeutic approach is essential. The pathogenesis of HE has not been well established. According to various scientific reports, neuropathological symptoms arise due to excessive accumulation of ammonia, which is transported to the brain via the blood-brain barrier (BBB), triggering oxidative stress and inflammation, and disturbing neuronal-glial functions. The treatment of HE involves eliminating hyperammonemia by enhancing the ammonia scavenging mechanism in systemic blood circulation. Melatonin is the sole endogenous hormone linked with HE. Melatonin as a neurohormone is a potent antioxidant that is primarily synthesized and released by the brain's pineal gland. Several HE and liver cirrhosis clinical studies have demonstrated impaired synthesis, secretion of melatonin, and circadian patterns. Melatonin can cross the BBB and is involved in various neuroprotective actions on the HE brain. Hence, we aim to elucidate how HE impairs brain functions, and elucidate the precise molecular mechanism of melatonin that reverses the HE effects on the central nervous system.

Indexed as

cognitive impairmenthepatic encephalopathyhyperammonemiamelatoninneuroinflammationneurotransmitter

Identifiers

PMID35624703
PMCPMC9137547
OpenAlexW4282929920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.